Literature DB >> 6323321

Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

J E Fuglesang, T Bergan.   

Abstract

Combinations of ampicillin and sulbactam (CP-45899) were tested against 11 strains of Escherichia coli and five strains of Klebsiella aerogenes. With the exception of one E. coli, strain, the strains were all highly resistant to ampicillin. Synergy was demonstrated by agar dilution in six of the ten resistant E. coli strains and in three of the five K. aerogenes strains. At simulated in vivo conditions with constantly decreasing concentrations mimicking in vivo pharmacokinetics, synergy was detected against the beta-lactamase-producing strains tested, although the activity against the more resistant K. aerogenes strains was low. The correlation between antibacterial activity as determined by minimum inhibitory concentrations and the bacterial kill kinetics exhibited in the in vivo simulation model was acceptable for E. coli. The relationship was less predictable for K. aerogenes, however.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323321     DOI: 10.1007/bf01641025

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Synergistic combinations of penicillins in the treatment of bacteriuria.

Authors:  L D Sabath; H A Elder; C E McCall; M Finland
Journal:  N Engl J Med       Date:  1967-08-03       Impact factor: 91.245

2.  Therapy with combinations of penicillin analogues in urinary-tract infections.

Authors:  L Riff; V M Olexy; G G Jackson
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

Review 3.  [Beta lactamase inhibitors, a new start of antibiotic therapy].

Authors:  W Wundt; M Baumgärtner
Journal:  Dtsch Med Wochenschr       Date:  1982-08-27       Impact factor: 0.628

4.  An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions.

Authors:  T Bergan; I B Carlsen; J E Fuglesang
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

6.  Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.

Authors:  B Olsson; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Inhibitory activity and bactericidal kinetics of mecillinam/ampicillin combinations against Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  J E Fuglesang; T Bergan; T Bielecki; A Naterstad; E Namork
Journal:  Infection       Date:  1981       Impact factor: 3.553

10.  Characterization and prevalence of the different mechanisms of resistance to beta-lactam antibiotics in clinical isolates of Escherichia coli.

Authors:  A A Medeiros; R L Kent; T F O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

View more
  2 in total

Review 1.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 2.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.